What it is
Selank is a synthetic heptapeptide (a chain of seven amino acids) engineered by the Institute of Molecular Genetics of the Russian Academy of Sciences. It's a stabilized analog of tuftsin, a naturally occurring immune-signaling peptide, with extra amino acids added so it survives longer in the body.
In Russia, Selank has been approved since 2009 as a prescription anxiolytic (brand name Selanc) for generalized anxiety disorder and neurasthenia, typically given as a nasal spray. It is NOT approved by the FDA or any Western regulator, and in the US and Europe it is sold only as a 'research use only' compound, not a medicine.
It is often grouped with Semax, another Russian peptide from the same research lineage, and marketed informally as a nootropic and anti-anxiety agent.
How it works
Selank appears to work through several overlapping systems rather than one target. Research suggests it modulates GABA (the brain's main calming neurotransmitter) and influences serotonin metabolism in the brainstem within about 30 minutes of dosing in animals. Animal work also shows it can raise BDNF, a protein that supports the growth and survival of neurons, in the hippocampus. These effects are proposed to explain its reported calming and mild cognitive benefits, though the exact receptor-level mechanism is not fully mapped.
A better-characterized action is its effect on enkephalins, the body's own opioid-like 'feel-good' peptides. In human plasma studies, Selank inhibited the enzymes that break enkephalins down, effectively prolonging their activity without directly activating opioid receptors. Researchers have proposed this enkephalin-stabilizing effect as a plausible driver of its anti-anxiety action.
What people research it for
Reduced anxiety without sedation
Early human dataRussian trials reported Selank eased generalized anxiety with an effect roughly comparable to benzodiazepines, but reportedly without heavy sedation, cognitive dulling, or dependence.
Anti-asthenic / anti-fatigue effect
Early human dataIn studies of neurasthenia, Selank was reported to reduce fatigue and low stress-tolerance alongside its calming effect, with a mild stimulating quality.
Possible cognitive/nootropic support
Animal studiesIts BDNF-raising and neurotransmitter effects are theorized to support memory and focus, but this is largely extrapolated from animal work.
Enkephalin and immune modulation
Preclinical / theorizedSelank stabilizes enkephalins and, via its tuftsin origin, shows immunomodulatory activity in lab studies.
What the research actually shows
The clinical evidence for Selank is almost entirely Russian. Small studies (often 30-60 patients) in people with generalized anxiety disorder and neurasthenia compared intranasal Selank against benzodiazepines like medazepam and reported similar anxiety reduction with added anti-fatigue effects and better tolerability. These findings underpinned its 2009 Russian approval.
The limits are significant and worth stating plainly. Most primary studies are published in Russian-language journals, sample sizes are small by Western Phase 3 standards, several were conducted at single sites, and some used active drugs rather than placebo as comparators. Independent replication by Western research groups has essentially not happened.
Mechanistic research (BDNF, GABA gene expression, enkephalin enzymes) is more accessible in English but is mostly animal or cell-based, so it explains how Selank might work rather than proving clinical benefit in people.
Research handling & storage
Selank is usually supplied as a lyophilized (freeze-dried) white powder that must be reconstituted, typically with bacteriostatic or sterile water. In its Russian medicinal form it is a 0.15% intranasal solution, and intranasal delivery is the most-studied route because the peptide is poorly absorbed if swallowed.
Reconstituted peptide is fragile: keep it refrigerated (roughly 2-8 degrees C), protect it from light and heat, and use it within a limited window. Sealed lyophilized powder is more stable and is generally kept frozen for long-term storage. All of this describes laboratory handling, not a human dosing protocol.
Safety & cautions
In the Russian literature Selank is described as well tolerated, non-sedating, and lacking the dependence or withdrawal seen with benzodiazepines, with few reported side effects. Because it is delivered intranasally, mild nasal irritation is the most commonly mentioned complaint.
That reassuring profile comes from limited data. There are no large, long-term Western safety trials, no FDA review, and little information on drug interactions or effects in vulnerable groups. Western-sold Selank is an unapproved 'research use only' chemical of variable purity, so its real-world safety in humans is genuinely uncertain.
Track Selank prices
Get an alert when a trusted, tested vendor drops the price. Free.
Frequently asked questions
Is Selank FDA approved?
No. Selank is approved as a prescription anxiolytic in Russia (since 2009) but has no FDA approval. In the US it is sold only as a research-use-only compound, not a medicine.
Selank vs Semax — what's the difference?
Both are Russian peptides from the same research institute. Selank is derived from tuftsin and is aimed mainly at anxiety and calming; Semax is derived from ACTH and leans more toward stimulation, focus, and neuroprotection. People sometimes describe Selank as the 'calming' one and Semax as the 'sharpening' one.
Does Selank cause sedation or dependence?
Russian studies report it does not cause the sedation, cognitive dulling, or dependence associated with benzodiazepines. However, long-term and independent safety data are lacking.
How is Selank taken in studies?
Almost always intranasally, because the peptide breaks down if swallowed. The Russian medicinal product is a nasal spray.
Is there strong Western evidence it works?
Not yet. The clinical trials are small, mostly Russian-language, and have not been independently replicated in the West, so the evidence base is early and geographically narrow.
Sources
- Zozulya et al. — Selank inhibits enkephalin-degrading enzymes (PubMed, 2001)
- Inozemtseva et al. — Intranasal Selank regulates BDNF in rat hippocampus (PubMed, 2008)
- Volkova et al. — GABA, Selank & GABAergic gene expression (Frontiers in Pharmacology, 2017)
- Selank — overview and regulatory status (Wikipedia)
Last reviewed 2026-07-07. This guide is educational and research-focused — not medical advice. Selank products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
Related peptides
Ready to compare Selank?
See prices across trusted, third-party-tested vendors, normalized per milligram.
Compare Selank prices →